Beth C. Seidenberg

Statistics

Publications

Citations

3.8K

H-Index

Active since

1998

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

University of Manitoba

United States Military Academy

Jean Brown Research

Bernstein Clinical Research Center

Beth C. Seidenberg is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacotherapy, pharmacology, and asthma pharmacotherapy.

Publications per year

1998–2001

Publications

Montelukast, a Leukotriene-Receptor Antagonist, for the Treatment of Mild Asthma and Exercise-Induced Bronchoconstriction

Jonathan A. Leff, David S. Pearlman, Edwin A. Bronsky et al. · New England Journal of Medicine · 1998 · 555 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14

Montelukast for Chronic Asthma in 6- to 14-Year-Old Children

Barbara Knorr, Jonathan Matz, Jonathan A. Bernstein et al. · JAMA · 1998 · 484 citations

Pharmacy, Pharmacology, Pharmacotherapy +13

Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis.

Elliot Ehrich, David J. Watson, James A. Bolognese et al. · PubMed · 2000 · 433 citations

Medicine, Orthopaedic Surgery, Pharmacotherapy +17

What are minimal important changes for asthma measures in a clinical trial?

Nancy C. Santanello, J. Zhang, Beth C. Seidenberg et al. · European Respiratory Journal · 1999 · 281 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: Results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip

Grant W. Cannon, Jacques R. Caldwell, Peter R. Holt et al. · Arthritis & Rheumatism · 2000 · 279 citations

Medicine, Pharmacology, Pharmacotherapy +15

1–5 of 18